Cicloderm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cicloderm

What is Cicloderm? Overview and Quick Facts

Property Description
Active ingredient Ciclopirox (often as Ciclopirox olamine)
Form Topical Cream, Solution, Shampoo, or Nail Lacquer
Pharmacological class Broad-spectrum Antifungal Agent
General purpose To manage dermatological infections caused by fungi and yeasts
Origin Synthetic Hydroxypyridone Derivative

What Type of Medicine is Cicloderm (Ciclopirox)?

Cicloderm is a prescription topical medication classified as a broad-spectrum antifungal agent, containing the single active ingredient Ciclopirox. This medicine is a synthetic compound that belongs to the unique hydroxypyridone derivative class, distinguishing it from common azole or allylamine antifungals. Its classification is recognized for efficacy against a wide spectrum of fungal organisms, including dermatophytes, yeasts, and molds, which are common causes of external dermatological infections. It is designed as a monoseptic product intended exclusively for external, dermatological use.

Composition and Available Forms of Ciclopirox

The active compound is typically present as Ciclopirox olamine, the salt form chosen to optimize stability within the product base. To ensure effective topical application on different areas, Cicloderm is prepared in various dosage forms, including a topical cream base, a liquid topical solution or suspension, a medicated shampoo base, and a specialized nail lacquer preparation. This versatility ensures the active agent can be delivered appropriately to the skin, scalp, or the rigid structure of the nail plate for managing localized infections.

What is the General Purpose of This Antifungal Agent?

The general purpose of the Ciclopirox compound is to stop the growth and replication of pathogenic fungi, yeasts, and molds, thereby managing and relieving external dermatological infections. Ciclopirox achieves this via a mechanism that involves the chelation of polyvalent metal ions within the fungal cell, effectively inhibiting the organism's vital metabolic processes. This antimycotic action addresses the infection and is complemented by a secondary, mild anti-inflammatory action, which helps reduce the local discomfort often associated with these external infections.

Regulatory References

  1. for managing localized infections (MedlinePlus Drug Information)

What side effects are possible with Cicloderm?

Possible Side Effects and Safety Information

This section outlines adverse reactions and safety constraints for Cicloderm (Ciclopirox Olamine/Ciclopirox) as documented in official government regulatory sources.


Frequency-Classified Adverse Reactions

The most frequent side effects are typically confined to the application site and are classified as Common in regulatory documents:

  • Burning sensation at the application site
  • Pruritus (itching)
  • Erythema (redness)

Uncommon reactions may include local hypersensitivity, headache, or reported cardiovascular effects such as palpitations or irregular heartbeat.


Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reaction involves the development of sensitization or chemical irritation at the application site. Symptoms such as increased burning, blistering, swelling, or oozing require that the use of the product be discontinued immediately.

Cicloderm is contraindicated in individuals with a known hypersensitivity to any of its components.

Regulatory Safety Constraints:

  • Not for ophthalmic use (do not use in the eyes).
  • Avoid the use of occlusive wrappings or dressings over the application area.

Population-Specific Safety Statements

Official regulatory sources specify cautions for certain populations:

  • Pregnancy: Classified as Pregnancy Category B. Use during pregnancy is limited to situations where the potential benefit is judged to outweigh the potential risk to the fetus.
  • Pediatrics: Safety and effectiveness have not been established in children below the age of 10 years for some formulations.

Overdose and Emergency Response

Overdose Manifestations and Expectations

Regulatory documentation on Cicloderm (ciclopirox topical) overdose confirms that a major risk is not anticipated from applying too much of the medication to the skin. Since the compound is a topical antifungal, systemic absorption is minimal, and an overdose resulting from excessive external application is officially stated as not expected to be dangerous. This regulatory classification reflects the low level of the active ingredient that typically reaches the bloodstream through the skin.


When to Seek Emergency Medical Attention

While topical overuse does not typically require intervention, accidental oral ingestion is the specific circumstance that triggers mandated emergency action. If the medication is accidentally swallowed, government regulators require the individual to seek immediate medical attention. This action is necessary to ensure proper assessment and management of potential systemic effects.


Management and Antidote Information

In the event of accidental ingestion, you should contact emergency services or a Poison Help line immediately, as this is the action explicitly described in the regulatory guidance. Official prescribing information confirms that no specific antidote is known for Ciclopirox overdose. Therefore, any management or intervention provided by a healthcare professional would be strictly symptomatic and supportive. No specific hospital monitoring or population-specific considerations (e.g., for the elderly or children) are explicitly documented in the official overdose sections.

Therapeutic Uses of Cicloderm

Cicloderm (ciclopirox olamine) is a medication utilized to help manage the common symptoms and manifestations of various superficial fungal infections of the skin. The drug is indicated for supporting the improvement of conditions such as tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm). It also addresses cutaneous candidiasis (fungal infections of the skin caused by Candida albicans) and tinea versicolor.

Quick Fact: Relief for Irritation Ciclopirox formulations are recognized for helping to calm the irritation and itchiness that frequently accompany common fungal skin flare-ups.

In these clinical situations, the treatment aims to provide symptomatic relief and support the resolution of visible signs, such as redness and scaling. Its use is part of a comprehensive management strategy intended to reduce discomfort.

Eligibility and Restrictions for Use

Cicloderm (Ciclopirox) is approved for use in specific populations as defined by regulatory bodies like the FDA, with key eligibility rules concerning hypersensitivity, age, and reproductive status.

Contraindicated Populations

Cicloderm is contraindicated in individuals with a known history of hypersensitivity or allergy to Ciclopirox or any of the product’s components. This is the only absolute exclusion stated in the labeling.

Age-Related Eligibility Rules

Age Group Eligibility Status (Cream/Suspension) Status (Gel/Shampoo)
Aged < 10 Years Use not established Use not established
Aged < 16 Years Established Use not established
Aged ≥ 16 Years Established Established

Conditional Use Populations

  • Pregnancy (Category B): Use is restricted to situations where the potential benefit is determined to justify the potential risk to the fetus, due to a lack of adequate and controlled studies in pregnant women.
  • Nursing Mothers: Caution should be exercised when the product is administered, as it is officially not known whether the drug is excreted in human milk.
  • Diabetic Patients (Nail Lacquer): For the nail lacquer formulation, use requires careful consideration in patients with insulin-dependent diabetes mellitus or diabetic neuropathy, due to limited clinical experience.

What should I know about interactions with other medicines?

The official regulatory profile for Cicloderm (Ciclopirox) interactions is primarily defined by the drug's topical route of administration and resulting minimal systemic absorption. For the topical cream and suspension formulations, regulatory documents indicate that systemic drug interaction studies have not been conducted, and clinically relevant systemic interactions are not expected due to the low plasma concentrations achieved.

Consequently, there are no documented metabolic, pharmacokinetic, or transporter-based interactions with Cicloderm in its most common topical forms. The official labeling states no contraindicated combinations related to drug interaction risk, and no timing-based administration rules requiring separation from other medicines, foods, alcohol, or herbal products are established.

A specific interaction-related restriction applies only to the Ciclopirox Topical Solution, 8% (nail lacquer). The prescribing information states that its concomitant use with systemic antifungal agents used to treat onychomycosis is not recommended. This constraint is based on a lack of studies confirming that Ciclopirox would not interfere with the efficacy of the systemic agent, rather than a documented change in drug levels. The overall interaction profile is characterized by the absence of documented systemic interaction risk.

Mechanism of Action

Targeted Fungal Metabolism via Essential Metal Chelation

The primary action of Ciclopirox involves it acting as a chelating agent, binding tightly to essential fungal cofactors, notably ferric iron ( Fe^3+). By sequestering these polyvalent cations, Ciclopirox deprives the pathogen of resources required for its vital metabolic processes. This step leads to the non-competitive inhibition of key mitochondrial enzymes, such as cytochromes, which are required for cellular energy production.


Breakdown of Cellular Respiration and Proliferation

The disruption caused by the chelation cascade results in the arrest of the fungal electron transport chain, leading to a failure in ATP synthesis (cellular energy). This energy deficit and the impairment of iron-dependent enzymes necessary for DNA and protein synthesis compromise the fungal cell's viability. The physiological consequence is the direct arrested proliferation and eventual structural death of the pathogen, which maintains a non-proliferative state in the tissue.


Modulation of Local Tissue Inflammation

Ciclopirox exerts a secondary effect by interacting with specific host pathways, primarily inhibiting enzymes like 5-Lipoxygenase (5-LO) in the arachidonic acid cascade. This mechanism reduces the local synthesis of inflammatory mediators, such as leukotrienes and prostaglandins. This physiological modulation involves a reduction in inflammatory mediator synthesis, which alters the local tissue response.

Dosage and Administration Information

How to Use Cicloderm (Ciclopirox)

Cicloderm (Ciclopirox) is designed for topical administration only, meaning it is applied directly to the external surface of the skin, scalp, or nails. The method, frequency, and duration of use are strictly dependent upon the specific dosage form and the location of the infection.


General Administration Principles

Usage Entity Official Instructions
Route of Administration Strictly Topical (Dermatological/External use).
Dosing Schedule Apply a thin layer to the affected and surrounding skin area (cream/solution), or coat the entire nail plate (lacquer).
Frequency Twice daily for creams and solutions; Once daily for the nail lacquer, typically applied at bedtime.

Duration and Procedural Requirements

The required course duration varies significantly. For superficial skin infections (e.g., tinea), treatment with the cream or solution is typically continued for 4 weeks. Conversely, treatment for onychomycosis using the nail lacquer requires an extended course, often lasting up to 48 weeks.

Administration requires adherence to specific procedures. The affected area should be cleansed before use. For the nail lacquer, preparatory steps include the removal of loose nail material before the first application, and the weekly removal of the existing film using a solvent to ensure proper drug penetration. The medication must not be applied to the eyes. For most formulations, use has been established for children 10 years of age and older.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cicloderm

The clinical evaluation of Cicloderm (Ciclopirox) is described in official research evidence, primarily from randomized controlled trials (RCTs), which compare the active medication to an inactive vehicle (placebo) or other established treatments. This evidence contributes to the broader scientific landscape by examining the medication's clinical evaluation across its approved uses.


Evidence for Use in Fungal Nail Infections (Onychomycosis)

The research exploring Ciclopirox nail lacquer was studied using long-term, double-blind Randomized Controlled Trials (RCTs). The main studies often extended over nearly one year. The primary populations included in this research were immunocompetent adults with mild to moderate fungal infections of the fingernails or toenails. Researchers monitored specific outcomes, including the elimination of the fungus (mycological status) and the clinical appearance of the nail, sometimes combining these into a composite endpoint for a measurement of overall effect.

Studies monitored the application of the nail lacquer alongside adjunctive professional removal (debridement) of the unattached infected nail tissue. Studies reported measurements of negative mycological status in a portion of the observed populations. However, trials also reported that the measurement of the composite endpoint (clear nail plus negative mycology) was low across the active treatment groups in these prolonged 48-week studies. The study results reflect the specific conditions under which they were conducted, which typically excluded patients whose infection involved the nail matrix.

Uncertainties and Research Gaps for Onychomycosis

Long-term effects are not fully established regarding the durability of the response after the end of the 48-week treatment period. Data remain limited for patients with more severe infections, such as those where the nail matrix is involved, and studies reported that research is limited for immunosuppressed patient populations.


Evidence for Use in Superficial Skin Fungi (Tinea and Candidiasis)

The research base for Ciclopirox creams and solutions against superficial fungal skin infections—such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and cutaneous candidiasisincludes multiple short-term to intermediate-term RCTs. These studies were conducted during periods of increased symptom activity and compared Ciclopirox formulations to an inactive vehicle or sometimes to an active comparator.

Researchers monitored a composite endpoint that required achieving both a negative culture and a change in visible symptoms. Research highlights changes measured in key clinical signs, such as scaling and erythema (redness). Studies also examined measurements of patient-reported discomfort (itching and burning) over a period typically lasting 28 days to 6 weeks.


Evidence for Use in Scalp Flaking and Itching (Seborrheic Dermatitis)

Ciclopirox shampoo was evaluated in short-term double-blind RCTs for conditions characterized by fluctuating or episodic manifestations, such as seborrheic dermatitis of the scalp. These studies focused on episodes where symptoms become more noticeable. They included adult populations, with outcomes measured on graded scales that assessed changes in symptom intensity related to scaling, redness, and patient-reported discomfort.

Research highlights changes measured during this short study period, describing patterns observed in the studies related to the change in clinical signs. These findings help contextualize how patients reported their experience with the condition, and studies contribute to the broader evidence landscape for conditions where symptoms may vary in intensity.

Key Studies & References

  1. MedlinePlus Drug Information: Ciclopirox topical
  2. Ciclopirox (Topical Use) and Pregnancy/Lactation Safety Review

Frequently Asked Questions (FAQ)

Common questions about Cicloderm (FAQ)


Q: Is Cicloderm the same type of drug as hydrocortisone?

No. According to the official product information, Cicloderm (Ciclopirox) is classified as a hydroxypyridone antifungal agent. Its mechanism involves binding to essential metal cations to inhibit fungal cell processes, which is chemically and functionally distinct from the mechanism of steroids like hydrocortisone.

Q: Is there a generic version of Cicloderm available?

Yes, Cicloderm is a brand name for the active ingredient Ciclopirox. The drug is widely available under its generic name from various manufacturers.

Q: What is the difference between Cicloderm cream and Cicloderm ointment?

The main difference lies in the inactive ingredients used to form the base. The cream is generally described as a water-miscible, vanishing cream base, while an ointment base contains a higher concentration of oils or other substances, which can affect skin penetration and feel.

Q: Why do doctors prescribe Cicloderm for seemingly different skin problems?

Official labeling indicates the drug is approved for the topical treatment of several distinct dermatological infections. These include various types of tinea (such as athlete's foot and ringworm), cutaneous candidiasis, and conditions characterized by flaking like seborrheic dermatitis.

Q: Is Cicloderm effective against fungal infections or is it only for inflammation?

Ciclopirox is primarily indicated as a broad-spectrum antifungal agent that works to inhibit the growth and proliferation of fungi. However, it also has a secondary anti-inflammatory effect by interacting with host enzymes in the arachidonic acid cascade, which may help reduce local swelling and redness associated with the infection.

Q: Do I need a prescription to get Cicloderm?

Yes. Official regulatory labels for Cicloderm are typically designated as 'Rx Only' (prescription only), meaning the medication must be prescribed by a licensed healthcare provider before it can be dispensed.

Q: What happens if I forget to use Cicloderm once?

Regulatory patient instructions often contain guidance regarding missed applications, such as using the dose when remembered. In situations where the next scheduled application time is near, the guidance generally provided is to skip the missed application and proceed with the next one as scheduled.

Q: Is it normal to feel a slight stinging or burning sensation when first applying Cicloderm?

A burning sensation at the application site is one of the most frequently reported adverse reactions, classified as Common in regulatory documents. Therefore, experiencing this sensation at the application site is a recognized possibility, as described in product safety data.

Q: Can I use Cicloderm at the same time as my regular moisturizer?

The official labeling does not specify a time separation for using Cicloderm alongside moisturizers. Official patient information often suggests discussing the use of any other topical products, including moisturizers, with a healthcare professional to avoid potential local irritation or effects on the medication.

Q: Does sun exposure while using Cicloderm increase any risks?

Official regulatory testing has specifically evaluated the potential for phototoxicity and photo-contact sensitization (reactions caused by light). The relevant studies conducted to assess these risks did not observe evidence of these effects in the tested subjects.

Q: Will Cicloderm help with persistent redness or discoloration?

Research studies for skin infections monitored erythema (redness) as a key clinical sign and measured changes during treatment. While the medication is not specifically indicated for cosmetic discoloration, its known anti-inflammatory action may help to reduce inflammatory redness associated with the treated condition.

Q: What is the shelf life of Cicloderm before it is opened?

The stability and expected quality of the medication are indicated by the expiration date printed on the packaging. This date reflects the period during which the product remains effective, provided it is stored according to the official instructions, usually at controlled room temperature.

Q: Can Cicloderm be used while pregnant or breastfeeding?

The drug is classified as Pregnancy Category B by the FDA, meaning its use during pregnancy is considered when the potential benefit outweighs the potential risk to the fetus. For breastfeeding, there is generally no human data available on its excretion into breast milk, and caution is typically advised by the manufacturer.

Q: Can children use Cicloderm, and are there different considerations for them?

For many formulations, safety and effectiveness have not been established in children below the age of 10 years. While some clinical trials have involved younger populations, label-based clearance is often restricted. The official labeling does not typically note different administration guidelines for the 10+ age group beyond the standard instructions.

Q: Why is Cicloderm restricted for people with certain health conditions?

The primary constraint is a contraindication (a condition that makes a particular treatment or procedure inadvisable) for individuals with a known hypersensitivity (allergy) to any of its components. Additionally, the nail lacquer formulation carries a special caution for patients with a history of insulin-dependent diabetes mellitus.

Q: Can Cicloderm be used in the genital area?

The product is strictly for external dermatological use only. Specific labeling for certain liquid formulations advises that the product is not for intravaginal use and that contact with mucous membranes should generally be avoided.

Q: Can older adults use Cicloderm without special precautions?

Official regulatory labeling states that no overall differences in safety or effectiveness have been noted between older and younger adult patients in clinical experience. The labeling does not typically contain different administration recommendations for geriatric patients.

Q: Does Cicloderm interact with common over-the-counter pain relievers like ibuprofen?

Clinically relevant systemic drug interactions are not expected due to the low plasma concentrations that result from minimal systemic absorption after topical use. Systemic interaction studies have generally not been conducted for the cream or solution formulations.

Q: Does Cicloderm interact with vitamins or herbal supplements?

The regulatory profile indicates no documented metabolic or systemic interactions with other substances. For overall safety, official patient information often includes a general recommendation to inform a healthcare provider of all medicines, herbs, non-prescription drugs, and dietary supplements being used.

Q: Can Cicloderm affect my blood sugar levels or other systemic measures?

Due to minimal systemic absorption, clinically significant systemic effects are generally not expected. However, a special caution is included on the nail lacquer product label for patients with a history of insulin-dependent diabetes mellitus.

Q: How long after stopping Cicloderm does it stay in your system?

Following topical absorption, the medication has a very short reported biological half-life of approximately 1.7 hours for the cream/lotion formulations. The absorbed portion is rapidly eliminated, primarily via the kidney.

Q: Are there restrictions on driving or operating machinery while using Cicloderm?

Official labeling does not list specific restrictions on driving or operating machinery. Adverse reactions are predominantly local, and given that systemic absorption is minimal, the official information does not typically note Central Nervous System (CNS) effects.

Q: What does Cicloderm's official regulatory labeling say about its potential for addiction or dependency?

Ciclopirox is not listed under any DEA schedule (Drug Enforcement Administration) and is not classified as a controlled substance by US regulatory authorities.

Q: What are the common reasons Cicloderm might not work for someone?

Official warnings state that a lack of response after the completion of the full prescribed course of treatment may indicate that the original condition was not sensitive to the medication or that the treatment duration was insufficient. Regulatory documents recommend that a lack of visible improvement after four weeks be discussed with a healthcare professional.

Q: How often do allergic reactions to Cicloderm occur?

Local hypersensitivity reactions are generally listed as Uncommon adverse reactions in regulatory documents. The most clinically significant reaction, involving increased irritation or sensitization, requires immediate discontinuation of the product.

Q: What are the eligibility requirements for someone to use Cicloderm?

Eligibility is generally based on having a fungal infection or condition for which the drug is indicated (such as tinea, candidiasis, or seborrheic dermatitis) and lacking any contraindications, such as a known allergy to the product or its components.

How should Cicloderm be stored and disposed of?

How to Store and Dispose of Cicloderm (Ciclopirox Olamine)

The storage and disposal of Cicloderm must adhere strictly to official regulatory guidelines to maintain its stability and ensure safety.


Official Storage Requirements

Requirement Specific Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Restrictions Do not freeze the product. The solution/lacquer is flammable and must be kept away from heat and flame.
Protection Keep the container tightly closed and protect it from light and excessive moisture.
Child Safety Store all formulations out of the sight and reach of children.

Disposal Instructions

Unused or expired Cicloderm must not be thrown into household trash or flushed down the toilet unless specifically authorized. Disposal must follow local, regional, and national regulations, often requiring return to an authorized drug take-back program to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cicloderm found in:

A-Z Index: